- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Xyphos Biosciences Inc.
Headquarters: South San Francisco, CA, United States
Website: N/A
Year Founded: 2017
Status: Acquired
BioCentury | Feb 21, 2024
Deals
Deal report: Astellas taps Kelonia for CAR Ts, Aurinia fails to find buyer, and more
Plus: Xoma-Kinnate, Almirall-Novo, Intellia-ReCode, Roche-Repare and more
BioCentury | May 1, 2023
Deals
Iveric takeout spotlights how Astellas builds in new areas of focus
The $5.9B ophthalmology deal also turns M&A attention to rival Apellis
BioCentury | Feb 7, 2023
Management Tracks
Astellas shuffles top management amid push to reshape strategically
As pharma implements growth plan to look beyond Xtandi, rising CEO Okamura figures to execute on launches, develop in newer modalities
BioCentury | Mar 24, 2020
Deals
With bispecifics deal, Astellas becomes CytomX’s first new partner since 2017
BioCentury | Dec 27, 2019
Product Development
Two-year-old Xyphos gains exit as Astellas scoops up CAR T switch platform
Xyphos’ animal data and focus on its CAR T switch platform paid off with Astellas takeout
BioCentury | Oct 25, 2019
Tools & Techniques
Gladstone, Xyphos target universal CARs to latent HIV
Gladstone, Xyphos target latent HIV with universal CARs to control safety, prevent escape
BioCentury | Oct 19, 2018
Company News
Xyphos, Parker Institute steer next-gen Car T therapies into solid tumors
BioCentury | Oct 18, 2018
Company News
Xyphos, Parker Institute steer next-gen CAR T therapies into solid tumors
Items per page:
1 - 9 of 9